Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte
stimulating hormone (alpha-MSH) in patients with acute renal failure.
II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute
renal failure after renal transplantation.
III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established
ischemic acute renal failure.
IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.